Unique characteristics of informal hospice cancer caregiving
the ONA take:
According to a recent study published in the journal Supportive Care in Cancer, researchers from the University of Missouri in Columbia and University of Washington in Seattle have identified unique characteristics of informal caregivers of patients with cancer that will ultimately help hospice providers to better address cancer caregivers' needs.
For the study, researchers analyzed data from a randomized clinical trial that included 348 informal hospice caregivers and compared the differences between cancer and non-cancer caregivers.
Results showed that informal caregivers of patients with cancer differed from non-cancer caregivers in respect to caregiver age, patient age, patient residence, amount and duration of care provided, relationship between caregiver and patient, likelihood to incur out-of-pocket expenses related to caring for the patient, effect on caregiver daily schedule, and caregiver problem-solving approach.
On the other hand, researchers found no significant differences between cancer caregivers and their non-cancer counterparts in regard to anxiety, employment status, gender, race, and quality of life.
The authors note that hospice providers can use these findings to customize supportive care interventions to more effectively address the needs of cancer caregivers.
Unique characteristics of informal caregivers of patients with cancer that will ultimately help hospice providers.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|